Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody

D. M. Mahvi, W. C. Meyers, R. C. Bast

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

DU-PAN-2 is a high molecular weight glycoprotein defined by a murine monoclonal antibody elicited to a pancreatic ductal adenocarcinoma cell line. This monoclonal antibody recognizes an oncofetal antigen present on the surface of pancreatic tumor cells. The antigen has also been detected in the sera of patients with adenocarcinoma of the pancreas by a competition radioimmunoassay (RIA). Ninety-four per cent (31/33) of patients with pancreatic adenocarcinoma in this study had DU-PAN-2 serum antigen levels greater than 300 units/ml by RIA, whereas sera from normal adults had serum levels less than 300 units/ml. Serial studies of DU-PAN-2 serum antigen in pancreatic cancer patients with elevated DU-PAN-2 serum levels (mean: 2873 units/ml) and surgically resectable neoplasms demonstrated a return to the normal range within 1 to 3 weeks after surgery in five of six patients. Five patients in clinical remission had normal DU-PAN-2 serum levels (mean: 110 units/ml). With tumor progression, however, the DU-PAN-2 level increased in all patients (mean: 2835 units/ml) an average of 2 months before evidence of progressive disease by clinical parameters. Serial DU-PAN-2 determinations are sensitive monitors of the progression of pancreatic cancer and may be useful as early indicators of response to therapy.

Original languageEnglish (US)
Pages (from-to)440-445
Number of pages6
JournalAnnals of Surgery
Volume202
Issue number4
StatePublished - Jan 1 1985

Fingerprint

Monoclonal Antibodies
Serum
Adenocarcinoma
Pancreatic Neoplasms
Antigens
Therapeutics
Radioimmunoassay
Neoplasms
Pancreas
Glycoproteins
Reference Values
Molecular Weight
Cell Line

ASJC Scopus subject areas

  • Surgery

Cite this

Mahvi, D. M., Meyers, W. C., & Bast, R. C. (1985). Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Annals of Surgery, 202(4), 440-445.
Mahvi, D. M. ; Meyers, W. C. ; Bast, R. C. / Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. In: Annals of Surgery. 1985 ; Vol. 202, No. 4. pp. 440-445.
@article{6465fdb10b944f29bf08ef3d914b726c,
title = "Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody",
abstract = "DU-PAN-2 is a high molecular weight glycoprotein defined by a murine monoclonal antibody elicited to a pancreatic ductal adenocarcinoma cell line. This monoclonal antibody recognizes an oncofetal antigen present on the surface of pancreatic tumor cells. The antigen has also been detected in the sera of patients with adenocarcinoma of the pancreas by a competition radioimmunoassay (RIA). Ninety-four per cent (31/33) of patients with pancreatic adenocarcinoma in this study had DU-PAN-2 serum antigen levels greater than 300 units/ml by RIA, whereas sera from normal adults had serum levels less than 300 units/ml. Serial studies of DU-PAN-2 serum antigen in pancreatic cancer patients with elevated DU-PAN-2 serum levels (mean: 2873 units/ml) and surgically resectable neoplasms demonstrated a return to the normal range within 1 to 3 weeks after surgery in five of six patients. Five patients in clinical remission had normal DU-PAN-2 serum levels (mean: 110 units/ml). With tumor progression, however, the DU-PAN-2 level increased in all patients (mean: 2835 units/ml) an average of 2 months before evidence of progressive disease by clinical parameters. Serial DU-PAN-2 determinations are sensitive monitors of the progression of pancreatic cancer and may be useful as early indicators of response to therapy.",
author = "Mahvi, {D. M.} and Meyers, {W. C.} and Bast, {R. C.}",
year = "1985",
month = "1",
day = "1",
language = "English (US)",
volume = "202",
pages = "440--445",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Mahvi, DM, Meyers, WC & Bast, RC 1985, 'Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody', Annals of Surgery, vol. 202, no. 4, pp. 440-445.

Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. / Mahvi, D. M.; Meyers, W. C.; Bast, R. C.

In: Annals of Surgery, Vol. 202, No. 4, 01.01.1985, p. 440-445.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody

AU - Mahvi, D. M.

AU - Meyers, W. C.

AU - Bast, R. C.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - DU-PAN-2 is a high molecular weight glycoprotein defined by a murine monoclonal antibody elicited to a pancreatic ductal adenocarcinoma cell line. This monoclonal antibody recognizes an oncofetal antigen present on the surface of pancreatic tumor cells. The antigen has also been detected in the sera of patients with adenocarcinoma of the pancreas by a competition radioimmunoassay (RIA). Ninety-four per cent (31/33) of patients with pancreatic adenocarcinoma in this study had DU-PAN-2 serum antigen levels greater than 300 units/ml by RIA, whereas sera from normal adults had serum levels less than 300 units/ml. Serial studies of DU-PAN-2 serum antigen in pancreatic cancer patients with elevated DU-PAN-2 serum levels (mean: 2873 units/ml) and surgically resectable neoplasms demonstrated a return to the normal range within 1 to 3 weeks after surgery in five of six patients. Five patients in clinical remission had normal DU-PAN-2 serum levels (mean: 110 units/ml). With tumor progression, however, the DU-PAN-2 level increased in all patients (mean: 2835 units/ml) an average of 2 months before evidence of progressive disease by clinical parameters. Serial DU-PAN-2 determinations are sensitive monitors of the progression of pancreatic cancer and may be useful as early indicators of response to therapy.

AB - DU-PAN-2 is a high molecular weight glycoprotein defined by a murine monoclonal antibody elicited to a pancreatic ductal adenocarcinoma cell line. This monoclonal antibody recognizes an oncofetal antigen present on the surface of pancreatic tumor cells. The antigen has also been detected in the sera of patients with adenocarcinoma of the pancreas by a competition radioimmunoassay (RIA). Ninety-four per cent (31/33) of patients with pancreatic adenocarcinoma in this study had DU-PAN-2 serum antigen levels greater than 300 units/ml by RIA, whereas sera from normal adults had serum levels less than 300 units/ml. Serial studies of DU-PAN-2 serum antigen in pancreatic cancer patients with elevated DU-PAN-2 serum levels (mean: 2873 units/ml) and surgically resectable neoplasms demonstrated a return to the normal range within 1 to 3 weeks after surgery in five of six patients. Five patients in clinical remission had normal DU-PAN-2 serum levels (mean: 110 units/ml). With tumor progression, however, the DU-PAN-2 level increased in all patients (mean: 2835 units/ml) an average of 2 months before evidence of progressive disease by clinical parameters. Serial DU-PAN-2 determinations are sensitive monitors of the progression of pancreatic cancer and may be useful as early indicators of response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022135866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022135866&partnerID=8YFLogxK

M3 - Article

C2 - 4051597

AN - SCOPUS:0022135866

VL - 202

SP - 440

EP - 445

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 4

ER -